Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Iovance Biotherapeutics, Inc. (IOVA : NSDQ)

• Company Description    Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells. Number of Employees: 838

• Price / Volume Information    Yesterday's Closing Price: $1.82 Daily Weekly Monthly 20 Day Moving Average: 14,776,782 shares Shares Outstanding: 361.85 (millions) Market Capitalization: $658.57 (millions) Beta: 0.87 52 Week High: $12.51 52 Week Low: $1.64 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.51% -17.22% 12 Week -18.39% -22.31% Year To Date -75.40% -78.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 825 INDUSTRIAL ROAD SUITE 400 - SAN CARLOS,CA 94070 USA ph: 650-260-7120 fax: - ir@iovance.com http://www.iovance.com

• General Corporate Information    Officers Frederick G. Vogt - Interim Chief Executive Officer and President; and Jean-Marc Bellemin - Chief Financial Officer and Treasurer Michael Weiser - Director Ryan D. Maynard - Director Wayne Rothbaum - Director Peer Information Iovance Biotherapeutics, Inc. (CORR.) Iovance Biotherapeutics, Inc. (RSPI) Iovance Biotherapeutics, Inc. (CGXP) Iovance Biotherapeutics, Inc. (BGEN) Iovance Biotherapeutics, Inc. (GTBP) Iovance Biotherapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 462260100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 361.85 Most Recent Split Date: 9.00 (0.01:1) Beta: 0.87 Market Capitalization: $658.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.22 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.87 Price/Cash Flow: - Price / Sales: 2.73 EPS Growth vs. Year Ago Period: 2.94% vs. Previous Quarter: 8.33% Sales Growth vs. Year Ago Period: 92.73% vs. Previous Quarter: 21.55% ROE 09/30/25 - - 06/30/25 - -52.87 03/31/25 - -49.71 ROA 09/30/25 - - 06/30/25 - -41.31 03/31/25 - -39.18 Current Ratio 09/30/25 - - 06/30/25 - 3.27 03/31/25 - 4.18 Quick Ratio 09/30/25 - - 06/30/25 - 2.89 03/31/25 - 3.64 Operating Margin 09/30/25 - - 06/30/25 - -161.44 03/31/25 - -176.49 Net Margin 09/30/25 - - 06/30/25 - -161.44 03/31/25 - -176.49 Pre-Tax Margin 09/30/25 - - 06/30/25 - -161.36 03/31/25 - -178.02 Book Value 09/30/25 - - 06/30/25 - 2.09 03/31/25 - 2.30 Inventory Turnover 09/30/25 - - 06/30/25 - 3.73 03/31/25 - 3.63 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©